Fresenius Kabi Usa Drug Patent Portfolio

Fresenius Kabi Usa owns 11 orange book drugs protected by 36 US patents with Acetaminophen having the least patent protection, holding only 1 patent. And Diprivan with maximum patent protection, holding 10 patents. Given below is the list of Fresenius Kabi Usa's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10398669 Levothyroxine liquid formulations 01 Dec, 2036
Active
US11135190 Levothyroxine liquid formulations 01 Dec, 2036
Active
US9782376 Levothyroxine liquid formulations 01 Dec, 2036
Active
US9271990 Fulvestrant formulations 17 May, 2034
Active
US9248229 Packaging system for oxygen-sensitive drugs 12 Mar, 2034
Active
US9072781 Morphine formulations 12 Mar, 2034
Active
US9192608 Morphine formulations 12 Mar, 2034
Active
US10188663 Fulvestrant formulations 14 Feb, 2034
Active
US9833459 Fulvestrant formulations 14 Feb, 2034
Active
US9636407 Caspofungin acetate formulations 21 Dec, 2032
Active
US8962572 Bortezomib formulations 03 Nov, 2032
Active
US9006289 Levothyroxine formulations 03 Oct, 2032
Active
US9168238 Levothyroxine formulations 29 Aug, 2032
Active
US9168239 Levothyroxine formulations 29 Aug, 2032
Active
US9731082 Drug container 23 Apr, 2032
Active
US8741959 Paracetamol for parenteral administration 19 Apr, 2030
Active
US7857802 Connector for medical liquid-containing packages and medical liquid-containing packages 28 Nov, 2026
Active
US7828787 Connector for packaging containing medical fluids and packaging for medical fluids 18 Oct, 2025
Active
US9566260 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 11 Jul, 2025
Active
US9629821 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 11 Jul, 2025
Active
US8476010 Propofol formulations with non-reactive container closures 01 Jun, 2025
Active
US8476010 Propofol formulations with non-reactive container closures 01 Dec, 2024
Active
US10350186 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 05 Nov, 2024
Active
US8162915 Connector for packings containing medical liquids, and corresponding packing for medical liquids 23 May, 2024 Expired
US8118802 Connector for packaging containing medical fluids and packaging for medical fluids 18 May, 2023 Expired
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020 Expired
US5714520 Propofol compostion containing edetate 22 Sep, 2015 Expired
US5731355 Pharmaceutical compositions of propofol and edetate 22 Sep, 2015 Expired
US5731356 Pharmaceutical compositions of propofol and edetate 22 Sep, 2015 Expired
US5908869 Propofol compositions containing edetate 22 Sep, 2015 Expired
US5714520 Propofol compostion containing edetate 22 Mar, 2015 Expired
US5731355 Pharmaceutical compositions of propofol and edetate 22 Mar, 2015 Expired
US5731356 Pharmaceutical compositions of propofol and edetate 22 Mar, 2015 Expired
US5908869 Propofol compositions containing edetate 22 Mar, 2015 Expired
US5670524 Methods and compositions for the treatment of pain utilizing ropivacaine 23 Sep, 2014 Expired
US5834489 Methods and compositions for the treatment of pain utilizing ropivacaine 26 May, 2014 Expired


Given below is the list of recent legal activities going on the following drug patents of Fresenius Kabi Usa.

Activity Date Patent Number
Patent litigations
Expire Patent 27 May, 2024 US8162915 (Litigated)
Expire Patent 25 Mar, 2024 US8118802 (Litigated)
Maintenance Fee Reminder Mailed 11 Dec, 2023 US8162915 (Litigated)
transaction for FDA Determination of Regulatory Review Period 01 Nov, 2023 US9566260
transaction for FDA Determination of Regulatory Review Period 19 Oct, 2023 US9566260
Maintenance Fee Reminder Mailed 09 Oct, 2023 US8118802 (Litigated)
Recordation of Patent eGrant 12 Sep, 2023 US11752164
Patent Issue Date Used in PTA Calculation 12 Sep, 2023 US11752164
Mail Patent eGrant Notification 12 Sep, 2023 US11752164
Email Notification 12 Sep, 2023 US11752164
Patent eGrant Notification 12 Sep, 2023 US11752164
Recordation of Patent Grant Mailed 12 Sep, 2023 US11752164
Email Notification 24 Aug, 2023 US11752164
Issue Notification Mailed 23 Aug, 2023 US11752164
Electronic Review 10 Aug, 2023 US11752164


Fresenius Kabi Usa's Drug Patent Litigations

Fresenius Kabi Usa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 06, 2015, against patent number US8476010. The petitioner Dr. Reddy's Laboratories, Inc., challenged the validity of this patent, with Fresenius Kabi USA, LLC as the respondent. Click below to track the latest information on how companies are challenging Fresenius Kabi Usa's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8476010 November, 2015 FWD Entered
(07 Jun, 2017)
Fresenius Kabi USA, LLC J Kyle Bass
US9006289 January, 2017 Terminated-Settled
(19 Apr, 2017)
Fresenius Kabi USA, LLC Mylan Institutional Inc.
US9168238 January, 2017 Terminated-Settled
(19 Apr, 2017)
Fresenius Kabi USA, LLC Mylan Institutional Inc.
US9168239 January, 2017 Terminated-Settled
(19 Apr, 2017)
Fresenius Kabi USA LLC Mylan Institutional Inc.
US9566260 March, 2014 Decision
(20 May, 2016)
Mark Puder et al
US8476010 February, 2015 Terminated-Denied
(02 Apr, 2015)
Fresenius Kabi USA, LLC Dr. Reddy's Laboratories, Inc.


Fresenius Kabi Usa Drug Patents' Oppositions Filed in EPO

Fresenius Kabi Usa drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 19, 2013, by Wibbelmann, Jobst. This opposition was filed on patent number EP10714862A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP10714862A Dec, 2013 Wibbelmann, Jobst Opposition rejected


Fresenius Kabi Usa's Family Patents

Fresenius Kabi Usa drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 32.5% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Fresenius Kabi Usa Drug List

Given below is the complete list of Fresenius Kabi Usa's drugs and the patents protecting them.


1. Acetaminophen

Acetaminophen is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8741959 Paracetamol for parenteral administration 19 Apr, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acetaminophen's drug page


2. Bortezomib

Bortezomib is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8962572 Bortezomib formulations 03 Nov, 2032
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bortezomib's drug page


3. Caspofungin Acetate

Caspofungin Acetate is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9636407 Caspofungin acetate formulations 21 Dec, 2032
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caspofungin Acetate's drug page


4. Dilaudid

Dilaudid is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9248229 Packaging system for oxygen-sensitive drugs 12 Mar, 2034
(9 years from now)
Active
US9731082 Drug container 23 Apr, 2032
(7 years from now)
Active
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid's drug page


5. Dilaudid-hp

Dilaudid-hp is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9248229 Packaging system for oxygen-sensitive drugs 12 Mar, 2034
(9 years from now)
Active
US9731082 Drug container 23 Apr, 2032
(7 years from now)
Active
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid-hp's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Diprivan

Diprivan is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8476010
(Pediatric)
Propofol formulations with non-reactive container closures 01 Jun, 2025
(7 months from now)
Active
US8476010 Propofol formulations with non-reactive container closures 01 Dec, 2024
(a month from now)
Active
US5714520
(Pediatric)
Propofol compostion containing edetate 22 Sep, 2015
(9 years ago)
Expired
US5731355
(Pediatric)
Pharmaceutical compositions of propofol and edetate 22 Sep, 2015
(9 years ago)
Expired
US5731356
(Pediatric)
Pharmaceutical compositions of propofol and edetate 22 Sep, 2015
(9 years ago)
Expired
US5908869
(Pediatric)
Propofol compositions containing edetate 22 Sep, 2015
(9 years ago)
Expired
US5714520 Propofol compostion containing edetate 22 Mar, 2015
(9 years ago)
Expired
US5731355 Pharmaceutical compositions of propofol and edetate 22 Mar, 2015
(9 years ago)
Expired
US5731356 Pharmaceutical compositions of propofol and edetate 22 Mar, 2015
(9 years ago)
Expired
US5908869 Propofol compositions containing edetate 22 Mar, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diprivan's drug page


7. Fulvestrant

Fulvestrant is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9271990 Fulvestrant formulations 17 May, 2034
(9 years from now)
Active
US10188663 Fulvestrant formulations 14 Feb, 2034
(9 years from now)
Active
US9833459 Fulvestrant formulations 14 Feb, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fulvestrant's drug page


8. Levothyroxine Sodium

Levothyroxine Sodium is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10398669 Levothyroxine liquid formulations 01 Dec, 2036
(12 years from now)
Active
US11135190 Levothyroxine liquid formulations 01 Dec, 2036
(12 years from now)
Active
US9782376 Levothyroxine liquid formulations 01 Dec, 2036
(12 years from now)
Active
US9006289 Levothyroxine formulations 03 Oct, 2032
(7 years from now)
Active
US9168238 Levothyroxine formulations 29 Aug, 2032
(7 years from now)
Active
US9168239 Levothyroxine formulations 29 Aug, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levothyroxine Sodium's drug page


9. Morphine Sulfate

Morphine Sulfate is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9072781 Morphine formulations 12 Mar, 2034
(9 years from now)
Active
US9192608 Morphine formulations 12 Mar, 2034
(9 years from now)
Active
US9248229 Packaging system for oxygen-sensitive drugs 12 Mar, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Morphine Sulfate's drug page


10. Naropin

Naropin is protected by 6 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7857802 Connector for medical liquid-containing packages and medical liquid-containing packages 28 Nov, 2026
(2 years from now)
Active
US7828787 Connector for packaging containing medical fluids and packaging for medical fluids 18 Oct, 2025
(1 year, 3 days from now)
Active
US8162915 Connector for packings containing medical liquids, and corresponding packing for medical liquids 23 May, 2024
(4 months ago)
Expired
US8118802 Connector for packaging containing medical fluids and packaging for medical fluids 18 May, 2023
(1 year, 4 months ago)
Expired
US5670524 Methods and compositions for the treatment of pain utilizing ropivacaine 23 Sep, 2014
(10 years ago)
Expired
US5834489 Methods and compositions for the treatment of pain utilizing ropivacaine 26 May, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naropin's drug page


11. Omegaven

Omegaven is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9566260 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 11 Jul, 2025
(8 months from now)
Active
US9629821 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 11 Jul, 2025
(8 months from now)
Active
US10350186 Treatment and prevention of liver disease associated with parenteral nutrition (PN) 05 Nov, 2024
(21 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omegaven's drug page